Stroma Targeting Antibody Production Service
Background Service Workflow Highlights Published Data FAQs Contact
Are you facing challenges with drug resistance in oncology, particularly due to the complex tumor microenvironment (TME)? Creative Biolabs' stroma targeting antibody production service helps you overcome these critical obstacles and accelerate your drug discovery process through advanced antibody engineering and high-throughput screening platforms. Our innovative solutions are designed to precisely target the tumor stroma, enhancing therapeutic efficacy and improving patient outcomes.
Introduction
The tumor microenvironment (TME), particularly its extracellular matrix (ECM) and cancer-associated fibroblasts (CAFs), plays a pivotal role in cancer progression and therapeutic resistance. ECM stiffness and CAF-mediated immunosuppression create formidable barriers to effective treatment. Stroma-targeting antibodies represent a groundbreaking approach to overcome these challenges, offering a means to remodel the TME, enhance drug delivery, and modulate immune responses, thereby improving the efficacy of existing and novel cancer therapies.
Fig.1 Schematic diagram of ECM components in normal tissues and the TME.1,3
Stroma Targeting Antibody Production Service at Creative Biolabs
Creative Biolabs' stroma targeting antibody production service focuses on the development of antibodies against components of the tumor ECM or stromal cells (e.g., CAFs, endothelial cells) to normalize the TME and enhance drug delivery. Our service delivers highly specific and effective antibody candidates designed to disrupt the pro-tumorigenic functions of the tumor stroma. Our solutions enable enhanced drug penetration, modulation of immune suppression, and direct targeting of stromal components that drive cancer progression and resistance.
We provide a comprehensive, end-to-end service, from target identification to validated antibody production, ensuring your project benefits from cutting-edge science and robust data. This includes biodistribution and pharmacokinetic (PK) characterization, such as radio-labeling services for in vivo imaging (e.g., PET, SPECT) to track antibody distribution and accumulation in target tissues, as well as PK/PD analysis support to evaluate half-life, clearance, and tissue distribution of antibody therapeutics.
Service Workflow
Key Advantages
- Customized Antibody Development: Tailored antibody development, including format and validation, aligns perfectly with your project's specific requirements.
- Advanced Antibody Discovery Platforms: Leverage cutting-edge platforms for diverse, high-affinity antibody discovery against challenging stromal targets.
- Comprehensive Functional Validation: Rigorous in vitro and in vivo testing in sophisticated TME models (3D co-cultures, microfluidics, PDX) confirms antibody efficacy in modulating stroma, enhancing drug penetration, and reprogramming immunity.
- Expertise in TME Biology: Our deep expertise in TME biology (ECM remodeling, CAF biology, immune suppression) guides optimal antibody design and development.
- Robust Quality Control: Stringent quality control, from antigen preparation to final antibody purification, ensures unparalleled product consistency and reliability.
- Seamless Integration with Downstream Applications: Our antibodies are produced with future applications in mind, including compatibility for antibody-drug conjugate (ADC) development, diagnostic assays, and combination therapies.
Representative Data
Summary: This study develops an antibody-drug conjugate targeting fibroblast activation protein (FAP) on CAF. It shows the antibody-drug conjugate selectively eliminates FAP-expressing cells in vitro and prolongs survival in xenograft models. Using a microfluidic platform, it finds treatment increases CAF secretion of proinflammatory cytokines (IL6, IL8) and CSF1, enhancing proinflammatory gene expression in cancer cells. Results indicate FAP-targeted therapy acts via modulating the immune microenvironment and promoting antitumor immune responses, supporting its potential as a cancer treatment.
Fig.2 Confocal microscopy technology detects the intracellular localization and distribution of antibody-drugs.2,3
FAQs
How do stroma-targeting antibodies improve drug delivery to tumors?
Stroma-targeting antibodies, such as those designed by Creative Biolabs to degrade components like hyaluronic acid or collagen, can physically break down the dense extracellular matrix. This remodeling reduces interstitial fluid pressure and creates pathways, allowing therapeutic agents to penetrate deeper and more uniformly into the tumor, significantly enhancing their efficacy.
Are Creative Biolabs' stroma-targeting antibodies specific enough to avoid off-target effects on healthy tissues?
Absolutely. Our antibody discovery platforms and rigorous screening processes are designed to identify antibodies with exceptional specificity for tumor-associated stromal markers, such as FAP, which are minimally expressed in normal adult tissues. We conduct comprehensive off-target binding assays to ensure high selectivity and a favorable safety profile.
What types of cancer can benefit most from stroma-targeting antibody approaches?
Stroma-targeting therapies are particularly promising for cancers characterized by a highly desmoplastic or immunosuppressive TME, such as pancreatic cancer, breast cancer, and colorectal cancer. These cancers often exhibit significant ECM stiffness and abundant CAFs, which our antibodies are designed to address.
Why Choose Us?
Creative Biolabs stands at the forefront of stroma-targeting antibody development, offering unparalleled expertise and innovative platforms. Our commitment to scientific rigor and client success ensures that you receive the highest quality antibodies tailored to your specific research and development needs. We leverage extensive experience in TME biology and antibody engineering to deliver solutions that truly make a difference in overcoming drug resistance.
Customer Reviews
"Creative Biolabs provided us with highly specific anti-FAP antibodies that allowed us to precisely target cancer-associated fibroblasts without affecting normal cells. This level of specificity was crucial for our ADC development, minimizing off-target toxicity and providing a clear therapeutic window. Their comprehensive characterization data gave us immense confidence in proceeding to preclinical trials." — 7 months ago, Dr. A***n M.
"The efficiency of Creative Biolabs' workflow, especially their rapid screening and validation in complex TME models, drastically cut down our research timeline. We were able to move from target identification to lead antibody selection in a fraction of the time it would have taken us internally, enabling us to focus on downstream applications. Their team's scientific support was exceptional." — 1 year ago, Dr. L***a K.
How to Contact Us
Ready to advance your cancer therapy project with targeted stroma solutions? Contact our expert team today to discuss your specific needs and learn how Creative Biolabs can empower your research.
Contact Our Team for More Information and to Discuss Your Project
References
- Huang, Jiacheng et al. "Extracellular matrix and its therapeutic potential for cancer treatment." Signal transduction and targeted therapy vol. 6,1 153. 23 Apr. 2021. DOI: https://doi.org/10.1038/s41392-021-00544-0
- Gallant, Joseph P et al. "Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody-Drug Conjugate Targeting Fibroblast Activation Protein." Cancer research communications vol. 4,6 (2024): 1481-1494. DOI: https://doi.org/10.1158/2767-9764.CRC-24-0248
- Distributed under Open Access License CC BY 4.0, without modification.
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
